Clinical trials: Malignancies Multiple
Multiple Myeloma
Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After Relapse
The purpose of this study is to determine whether giving linvoseltamab with lenalidomide during maintenance treatment to participants with multiple myeloma will: 1.
- Trial name
- NCT06910124
- Testing
- Linvoseltamab, Lenalidomide
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Dickran Kazandjian, MD
Lymphoma, B-Cell
Study of Pralatrexate to Treat Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
The purpose of this study is to determine whether pralatrexate, given with vitamin B12 and folic acid, is effective in the treatment of relapsed or refractory B-cell Non-Hodgkin's lymphoma (NHL).
- Trial name
- NCT00998946
- Testing
- Pralatrexate, Vitamin B12, Folic Acid
- Where
- 11 sites in United States
- Volunteers
- 29 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple Myeloma
This phase II trial studies how well lenalidomide and nivolumab work in treating patients with multiple myeloma that has come back or does not respond to treatment.
- Trial name
- NCT03333746
- Testing
- Laboratory Biomarker Analysis, Lenalidomide, Nivolumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Yvonne Efebera
Mycosis Fungoides
Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion Protein in Subjects With Mycosis Fungoides
This study evaluates the effectiveness - as judged by complete response - of a single four-day treatment with the fusion protein A-dmDT390-bisFv(UCHT1) compared to oral Zolinza (Vorinostat), in a randomized 2-arm trial after a…
- Trial name
- Resimmune® (NCT02943642)
- Testing
- A-dmDT390-bisFv(UCHT1), Vorinostat
- Sponsor
- Virogen Biotechnology Inc.
HER2-positive Gastric Cancer
Study to Evaluate the Safety and Efficacy of Tislelizumab in Combination With Zanidatamab as a 2nd Line in HER2-Positive Advanced Gastric Cancer in K-Umbrella Trial
Study Design: This is a Phase II study to assess the safety and clinical efficacy of this combined chemotherapy-free regimen (zanidatamab and tislelizumab) in HER2-positive advanced gastric/gastroesophageal junction (GEJ)…
- Trial name
- NCT05270889
- Testing
- Tislelizumab+Zanidatamab
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Yonsei University
Generalized Myasthenia Gravis (gMG)
An Open-label, Dose-escalation Phase Ib Study of EA5 Injection in Adults With Anti-AChR Antibody-Positive Generalized Myasthenia Gravis
This is a Phase Ib, open-label, dose-escalation, single-center/multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of multiple doses of EA5 (a humanized…
- Trial name
- NCT07818291
- Testing
- EA5
- Where
- 2 sites in China
- Volunteers
- 18 people
- Sponsor
- Shanghai Lanyi Therapeutics Co., Ltd.
Brain and Central Nervous System Tumors
Temozolomide and Radiation Therapy in Treating Young Patients With Pontine Glioma
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00514397
- Testing
- motexafin gadolinium, temozolomide, adjuvant therapy
- Where
- 21 sites in Ireland, United Kingdom
- Volunteers
- 43 people
- Sponsor
- Children's Cancer and Leukaemia Group
Cancer
Integrated Short-Term Palliative Rehabilitation in Incurable Cancer
The goal of this intervention trial is to determine if palliative rehabilitation in addition to usual care is more effective than usual care at improving health-related quality of life in patients with incurable solid cancer.
- Trial name
- INSPIRE (NCT05984797)
- Testing
- Integrated Short-term Palliative Rehabilitation
- Where
- 11 sites in Denmark, France and 3 more
- Volunteers
- 340 people
- Sponsor
- King's College London
Head and Neck Cancer
A Study of [F-18]HX4 (PET Imaging)Evaluated in Head and Neck Cancer Patients
The purpose of this trial is to determine what will be the optimal imaging protocol for Head and Neck Cancer patients after [F-18] HX4 injection.
- Trial name
- NCT01506427
- Testing
- [F-18] HX4
- Where
- United States
- Sponsor
- Siemens Molecular Imaging
Lung Cancer, Organoid
Organoids Predict Therapeutic Response in Patients With Multi-line Drug-resistant Lung Cancer
This is a single-center, single-arm, open and exploratory clinical study. The purpose of this study was to evaluate the consistency and accuracy of the organogenic (PDO) model for patients with lung cancer, to predict the…
- Trial name
- NCT05669586
- Testing
- Antitumor therapy guided by organoid drug sensitivity test
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Affiliated Hospital of Jiangnan University
Unspecified Adult Solid Tumor, Protocol Specific
PR104 and G-CSF in Treating Patients With Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as PR-104, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00616213
- Testing
- filgrastim, PR104, F-18-fluoromisonidazole
- Where
- 3 sites in United States, New Zealand
- Volunteers
- 5 people
- Sponsor
- Proacta, Incorporated
Ovarian Neoplasms
Pilot Study of Taxol, Carboplatin, and Bevacizumab in Advanced Stage Ovarian Carcinoma Patients
The most likely way to improve survival and cure rates in treating ovarian cancer, fallopian tube epithelial cancer, and peritoneal cancer is with maximal "upfront" therapy (Morrow \& Curtin, 1998).
- Trial name
- NCT00127920
- Testing
- Avastin
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Gynecologic Oncology Associates
Peripheral T-Cell Lymphoma
Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL)
The primary objective of this study is to determine the overall response rate of KW-0761 for the treatment of patients with relapsed or refractory PTCL. KW-0761 targets CCR4.
- Trial name
- NCT01611142
- Testing
- KW-0761 (mogamulizumab)
- Where
- 15 sites in Denmark, France and 4 more
- Volunteers
- 38 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Multiple Myeloma
Pharmacokinetic Study of Thalidomide in Subjects With Multiple Myeloma
Objective of this study is to characterize the steady-state pharmacokinetics (PK) of thalidomide when given orally as monotherapy to subjects with multiple myeloma.
- Trial name
- NCT01937442
- Testing
- Thalidomide Celgene™
- Where
- 7 sites in France, United Kingdom
- Volunteers
- 7 people
- Sponsor
- Celgene
Neuroendocrine Neoplasm, Neuroendocrine Neoplasm of Gastrointestinal Tract
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients
Neuroendocrine neoplasms (NENs) are a heterogeneous group of lesions derived from cells with the ability to produce hormones that may arise from multiple different organs.
- Conditions
- Neuroendocrine Neoplasm, Neuroendocrine Neoplasm of Gastrointestinal Tract, Neuroendocrine Neoplasm of Lung, Thymic Neuroendocrine Neoplasm
- Trial name
- NCT06523582
- Where
- 3 sites in Mexico
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- Universidad Nacional Autonoma de Mexico
Hematologic Malignancies, Relapse
Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies
The investigators hypothesize that adding carfilzomib to standard conditioning regimen for allo-HCT for advanced or high-risk hematologic malignancies will decrease post-transplant relapse and treatment-related mortality by…
- Conditions
- Hematologic Malignancies, Relapse, Graft-Versus-Host Disease
- Trial name
- NCT02145403
- Testing
- Carfilzomib, Tacrolimus
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- University of Michigan Rogel Cancer Center
Non-small Cell Lung Cancer NSCLC
Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)
This is a randomized, double-blind, multi-center, global Phase II study to determine the efficacy and safety of Durvalumab plus Olaparib combination therapy compared with Durvalumab monotherapy as maintenance therapy in patients…
- Trial name
- ORION (NCT03775486)
- Testing
- Durvalumab, Olaparib, Nab-paclitaxel+carboplatin
- Where
- 68 sites in United States, Belgium and 10 more
- Volunteers
- 401 people
- Sponsor
- AstraZeneca
Margin Assessment, Breast Cancer
Spectral Cancer Tissue Recognition - I
This analytical performance study aims to validate the SPCTRone system for use in breast conserving surgery of breast cancer patients.
- Trial name
- SPCTR-I (NCT07459062)
- Where
- 2 sites in Netherlands
- Volunteers
- 100 people
- Sponsor
- SPCTR
Multiple Myeloma
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65
In this research study, we are looking to explore the drug combination, lenalidomide, bortezomib and dexamethasone alone or when combined with autologous stem cell transplantation to see what side effects it may have and how well…
- Trial name
- DFCI 10-106 (NCT01208662)
- Testing
- Lenalidomide, Bortezomib, Dexamethasone
- Where
- 46 sites in United States
- Volunteers
- 729 people
- Sponsor
- Paul Richardson, MD
Multiple Myeloma
Real-world Use of Carfilzomib Among Multiple Myeloma Patients in Europe
With the recent addition of carfilzomib as a treatment option for multiple myeloma, no data is available yet on how the drug is being used outside of the clinical trial setting.
- Trial name
- NCT03091127
- Where
- 114 sites in Austria, Belgium and 9 more
- Volunteers
- 705 people
- Sponsor
- Amgen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.